vorinostat has been researched along with Animal Mammary Carcinoma in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Zhao, Y | 1 |
| Jiang, W | 1 |
| Li, S | 1 |
| Zhan, M | 1 |
| Liu, H | 2 |
| Zhang, C | 1 |
| Liang, H | 1 |
| Lu, L | 1 |
| Wang, Y | 1 |
1 other study available for vorinostat and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Ultralong circulating choline phosphate liposomal nanomedicines for cascaded chemo-radiotherapy.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Hypoxia; Chemoradiotherapy; Female; Liposomes; | 2019 |